PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study

Autor: SIRIMA, S. B., Richert, Laura, Chene, A., KONATE, A. T., CAMPION, Cecilia, Dechavanne, S., SEMBLAT, J. P., BENHAMOUDA, N., BAHUAUD, M., Loulergue, P., NEBIE, I., Kabore, M., KARGOUGOU, D., Barry, A., OUATTARA, S. M., BOILET, Valerie, Allais, Florence, Roguet, G., HAVELANGE, N., LOPEZ-PEREZ, E., KUPPERS, A., KONATE, E., Roussillon, Caroline, KANTE, Myriam, BELARBI, L., DIARRA, A., Henry, N., SOULAMA, I., Ouedraogo, A., Esperou, H., Leroy, O., Batteux, F., TARTOUR, E., VIEBIG, N. K., THIEBAUT, Rodolphe, Launay, O., Gamain, B.

Publikováno v: The Lancet Infectious Diseases
The Lancet Infectious Diseases, New York, NY : Elsevier Science ; The Lancet Pub. Group, 2001-, 2020, 20 (5), pp.585-597. ⟨10.1016/s1473-3099(19)30739-x⟩

International audience; BackgroundPRIMVAC is a VAR2CSA-derived placental malaria vaccine candidate aiming to prevent serious clinical outcomes of Plasmodium falciparum infection during pregnancy. We assessed the safety and immunogenicity of PRIMVAC a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::1bbe79b2151c7f5a4a8a3f1fb8e460c5
https://hal.archives-ouvertes.fr/hal-03161802